Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review
Open Access
- 8 August 2019
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 8 (12) , 5414-5424
Abstract
Background: Melanoma is a potentially fatal malignancy with poor prognosis. Several recent studies have demonstrated that combination therapy of BRAF and MEK inhibition achieved better curative effect and appeared less toxic effects. We conducted a meta‐analysis to evaluate the efficacy and safety between BRAF inhibition plus MEK inhibition combination therapy and BRAF inhibition monotherapy in melanoma patients.Methods: We performed the search in PubMed, EMBASE, and the Cochrane Library from January 2010 to January 2019. Inclusion and exclusion of studies, assessment of quality, outcome measures, data extraction, and synthesis were independently accomplished by two reviewers. Revman 5.3 software was used for the meta‐analysis.Results: Totally, seven randomized controlled trials involving 3146 patients met our inclusion criteria. Comparing the results of combination therapy and monotherapy, combination therapy significantly improved OS (RR = 1.13; 95% CI, 1.08, 1.19; P < 0.00001), ORR (RR = 1.36; 95% CI, 1.28, 1.45; P < 0.00001), PFS (RR = 0.57; 95% CI, 0.52, 0.63; P < 0.00001) and reduced deaths (RR = 0.78; 95% CI, 0.69, 0.88; P < 0.0001). Skin‐related adverse events such as hyperkeratosis, cutaneous squamous‐cell carcinoma were less compared with monotherapy. However, gastrointestinal events like nausea, diarrhea, and vomiting were at a higher frequency.Conclusion: Doublet BRAF and MEK inhibition achieved better survival outcomes over single‐agent BRAF inhibition and occurred less skin‐related events, but gastrointestinal events were more in combination therapy.Keywords
Funding Information
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
This publication has 44 references indexed in Scilit:
- BRAF and MEK inhibition in melanomaExpert Opinion on Drug Safety, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibNew England Journal of Medicine, 2015
- Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialAnnals of Oncology, 2014
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated MelanomaNew England Journal of Medicine, 2014
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- Treating advanced melanoma: current insights and opportunitiesCancer Management and Research, 2014
- Management of melanomaBritish Medical Bulletin, 2014
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaCancer Management and Research, 2012
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsNew England Journal of Medicine, 2012